Recurrent Verrucous Carcinoma of the Larynx Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029506 (Recurrent Verrucous Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment